AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., May 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday, May 14, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
加利福尼亞州千橡市，2024年5月9日 /PRNewswire/ — 安進（納斯達克股票代碼：AMGN）將於太平洋時間2024年5月14日星期二上午9點20分出席美國銀行美林證券全球醫療保健會議。安進執行副總裁兼首席財務官彼得·格里菲斯和安進研發執行副總裁兼首席科學官傑伊·布拉德納將出席會議。網絡直播將同時通過互聯網播出，並將向新聞媒體成員、投資者和公衆開放。
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
該網絡直播，以及管理層在某些投資者和醫療會議上發表的關於安進業務發展的其他精選演講，可以在安進的網站上找到， www.amgen.com，在 “投資者” 下。安進的投資者關係活動日曆上註明了有關演講時間、網絡直播可用性和網絡直播鏈接的信息。網絡直播將在活動結束後至少 90 天內存檔並可供重播。
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
關於安進
安進發現、開發、製造和交付創新藥物，以幫助數百萬患者對抗世界上一些最棘手的疾病。40多年前，安進幫助建立了生物技術行業，並一直處於創新的前沿，利用技術和人類遺傳數據來超越當今的已知水平。安進正在推進廣泛而深入的產品線，該產品線建立在其現有藥物組合的基礎上，用於治療癌症、心臟病、骨質疏鬆症、炎症性疾病和罕見疾病。
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average, and it is also part of the Nasdaq-100 Index, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
2024年，安進被Fast Company評爲 “全球最具創新力的公司” 之一，被《福布斯》等評爲 “美國最佳大型僱主” 之一 外部識別。安進是構成道瓊斯工業平均指數的30家公司之一，它也是納斯達克100指數的一部分，其中包括按市值在納斯達克股票市場上市的最大、最具創新性的非金融公司。
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads.
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
聯繫人：安進、千橡市
Elissa Snook，609-251-1407（媒體）
賈斯汀·克萊斯，805-313-9775（投資者）
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-302141537.html
SOURCE Amgen
來源 Amgen